<DOC>
	<DOC>NCT00432510</DOC>
	<brief_summary>The study objective was to describe the pharmacokinetics (PK) of one or two doses of C1 esterase inhibitor (C1INH-nf) in hereditary angioedema (HAE) subjects who were not experiencing an HAE attack.</brief_summary>
	<brief_title>Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas, Hereditary</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Enrolled in LEVP20051 (current or in the past) C1 inhibitor infusion within the last 7 days Signs of any HAE attack HAE attack within 7 days before actual infusion of C1INHnf Change in the dosage of androgens in the last 14 days before the study Use of antifibrinolytics in the last 7 days before the study Change in oral conceptive medication in the last two months before the study History of clinically relevant antibody development to C1 inhibitor Use of oral anticoagulant medication in the last 14 days Use of heparin within the last two days prior to the study History of allergic reaction to C1 inhibitor or other blood products Current participation (or within the past 90 days) in any investigational drug study other than those sponsored by Lev Pharmaceuticals Pregnancy or lactation Bcell malignancy Any clinically significant medical condition, such as renal failure, that in the opinion of the investigator would interfere with the subject's ability to participate in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hereditary angioedema</keyword>
	<keyword>C1 esterase inhibitor (human)</keyword>
</DOC>